JPRN-jRCT2080221847
未知
3 期
A long-term clinical study of OPC-262 in patients with type 2 diabetes (Extension study from Study 262-09-001)
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- type 2 diabetes
- 发起方
- Otsuka Pharmaceutical Co., Ltd.
- 入组人数
- 175
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •(1\) Patients who completed Study 262\-09\-001 (patients who visited the hospital at visit Week 24\)
- •(2\) Patients who are capable of giving informed consent prior to participating in this clinical study
- •(3\) Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner
排除标准
- •(1\) Patients who withdrew fyom Study 262\-09\-001
- •(2\) Patients who experienced serious adverse events that the relationship with the study drug was not denied in Study 262\-09\-001
- •(3\) Patients who experienced serious adverse events that the relationship with the study drug are denied in Study 262\-09\-001 and whose symptoms are still emerged at the time of initiation of this study
- •(4\) Patients who met the exclusion criteria of Study 262\-09\-001 during the study period of Study 262\-09\-001
- •(5\) Female patients who wish to become pregnant during the study period of Study 262\-09\-002 or within 4 weeks after the study
- •(6\) Patients other wise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study
结局指标
主要结局
未指定
相似试验
未知
3 期
A Phase 3 Study of OPC-262 in patients with type 2 diabetesPatients with type 2 diabetesJPRN-jRCT2080220920Otsuka Pharmaceutical Co., Ltd.100
已完成
3 期
Along-term Study of OPC-262 in Patients With Type 2 DiabetesDiabetes, Type 2NCT01634282Kyowa Kirin Co., Ltd.222
已完成
3 期
A Study of OPC-262 in Patients With Type 2 DiabetesType 2 DiabetesNCT01046318Kyowa Kirin Co., Ltd.100
未知
3 期
ong-term co-administration study of OPC-262 in patients with type 2 diabetes mellitustype 2 diabetesJPRN-jRCT2080221215Otsuka Pharmaceutical Co., Ltd.
未知
2 期
A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetespatients with type 2 diabetesJPRN-jRCT2080220672Otsuka Pharmaceutical Co., Ltd.280